ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

セファレキシン

Cephalexin

HCID 27447
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
15686-71-2
標準SMILES
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1
InChIKey
ZAIPMKNFIOOWCQ-UEKVPHQBSA-N
分子式
C16H17N3O4S
平均分子量
347.4 g/mol
単同位体質量
347.09397721

概要

Cephalexin is a semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract. It has a role as an antibacterial drug. It is a cephalosporin, a semisynthetic derivative and a beta-lactam antibiotic allergen. It is a conjugate acid of a cephalexin(1-).

名称と識別子

優先名称
Cephalexin
IUPAC
(6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
現地名
セファレキシン
英語名
Cephalexin
分子式
C16H17N3O4S
分子量
347.39

名称と別名

cephalexinCefalexin15686-71-2CephacillinCeporexinMamalexinCeporexKeflexCarnosporinCefaleksinCephalexineCephalexinum
名称をさらに表示
タイセレキシンセポレックスL-ラスポリジンセポレキシンセファザールセファレキシン(無水物)ケフレックスイワレキシンガラシンシーエックスセファレキシンスシラリントキオレキシンメピラシンデランテールセンセファリンマドレキシンセファロマックスL-キサール(6R)-7α-[(R)-2-アミノ-2-フェニルアセチルアミノ]-3-メチル-8-オキソ-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸CEFALEXIN SODIUMoroxincexs6437syncloracefkeforal
CeporexineSinthecillinUphalexinAlsporinCepexinDurantelFelexinPyassan

データベース識別子

CAS
15686-71-2、23325-78-2

物性

構造計算による物性

XLogP
0.6
極性表面積
138 Ų
水素結合供与体数
3
水素結合受容体数
6
回転可能結合数
4
重原子数
24
形式電荷
0
複雑度
600

実験および物理化学的性質

Drugs · 3 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Antibiotics (Cefalosporins)

Pharmaceuticals -> Antibiotics

LogPlogP = 0.65
Color/Form · 2 件

CRYSTALS

WHITE TO OFF-WHITE, CRYSTALLINE POWDER

Solubility · 3 件

10mg/mL

SLIGHTLY SOL IN WATER; PRACTICALLY INSOL IN ALC, CHLOROFORM, ETHER

2.97e-01 g/L

Human Drugs · 4 件

Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antibacterial Agents; Cephalosporins

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Access group antibiotics

Animal Drugs · 4 件

EMA approved medicines: Veterinary medicine

FDA approved animal drugs -> Active ingredient

Pharmaceuticals -> UK Veterinary Medicines Directorate List

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

Melting Point326.8 °C
Physical DescriptionSolid

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]

P233, P260, P261, P271, P272, P280, P284, P302+P352, P304+P340, P321, P333+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 75 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information · 2 件

5-Thia-1-azabicyclo4.2.0oct-2-ene-2-carboxylic acid, 7-(2R)-aminophenylacetylamino-3-methyl-8-oxo-, (6R,7R)-: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Cephalexin: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-methyl-8-oxo-, [6R-[6.alpha.,7.beta.(R*)]]-: Human health tier I assessment
FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Hazard Classes and CategoriesSkin Sens. 1 (100%)

安全と保護具

Storage Conditions · 1 件

化学と産業

薬理情報

ATC Code · 5 件

J01DB01

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

J01DB01

Protein BindingCephalexin is 10-15% bound to serum proteins including serum albumin.
Pharmacodynamics · 1 件

Cephalexin (also called Cefalexin) is a first generation cephalosporin antibiotic. It is one of the most widely prescribed antibiotics, often used for the treatment of superficial infections that result as complications of minor wounds or lacerations. It is effective against most gram-positive bacteria through its inihibition of the cross linking reaction between N-acetyl muramicacid and N-acetylglucosamine in the cell wall, leading to cell lysis.

Mechanism of Action · 5 件

Cephalexin is a first generation cephalosporin antibiotic. Cephalosporins contain a beta lactam and dihydrothiazide. Unlike penicillins, cephalosprins are more resistant to the action of beta lactamase. Cephalexin inhibits bacterial cell wall synthesis, leading breakdown and eventualy cell death.

CEPHALOTHIN & ITS CONGENERS INHIBIT BACTERIAL CELL-WALL SYNTHESIS IN MANNER SIMILAR TO THAT OF PENICILLIN. /CEPHALOSPORINS/

The penicillins and their metabolites are potent immunogens because of their ability to combine with proteins and act as haptens for acute antibody-mediated reactions. The most frequent (about 95 percent) or "major" determinant of penicillin allergy is the penicilloyl determinant produced by opening the beta-lactam ring of the penicillin. This allows linkage of the penicillin to protein at the amide group. "Minor" determinants (less frequent) are the other metabolites formed, including native penicillin and penicilloic acids. /Penicillins/

Bactericidal; action depends on ability to reach and bind penicillin-binding proteins located in bacterial cytoplasmic membranes; cephalosporins inhibit bacterial septum and cell wall synthesis, probably by acylation of membrane-bound transpeptidase enzymes. This prevents cross-linkage of peptidoglycan chains, which is necessary for bacterial cell wall strength and rigidity. Also, cell division and growth are inhibited, and lysis and elongation of susceptible bacteria frequently occur. Rapidly dividing bacteria are those most susceptible to the action of cephalosporins. /Cephalosporins/

関連反応

12 件
反応記録を作成
HRID 35993 の反応式
HRID 35993反応物として
HRID 126681 の反応式
HRID 126681生成物として
HRID 236422 の反応式
HRID 236422反応物として
HRID 454793 の反応式
HRID 454793反応物として
HRID 616226 の反応式
HRID 616226生成物として
HRID 867605 の反応式
HRID 867605反応物として
HRID 914651 の反応式
HRID 914651生成物として
HRID 1076547 の反応式
HRID 1076547生成物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
PubChem CID
27447
DTXSID
DTXSID9022780
ChEMBL
CHEMBL1200544、CHEMBL1727
ChEBI
CHEBI:3534
UNII
5SFF1W6677
EC Number
239-773-6
Nikkaji
J3.133J
Stability/Shelf Life
ACID-STABLE
Dissociation Constants · 3 件

2.53

7.14

PKA: 5.2, 7.3

Collision Cross Section · 4 件

178.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

163.36 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

183.1 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with Waters Major Mix]

179.56 Ų [M-H]-

物理化学的性質

融点
196 · 196-198°C
比旋光度
20 · [α]D20 +144~+158° (c=0.5, H2O) (Calculated on dehydrous basis)
沸点
727.4 · 727.4±60.0 °C(Predicted)
比重(密度)
1.304 · 1.3040 (rough estimate)
屈折率
1.632 · 1.6320 (estimate)
貯蔵温度
2 · Keep in dark place,Inert atmosphere,2-8°C
溶解性
4 OH · NH4OH 1 M: 50mg/mL、透明、黄色
酸解離定数(Pka)
5.2 · 5.2, 7.3(at 25℃)
外見
Solid
色
White to light yellow
PH
5 g/l, · pH (5g/l, 25℃) 3.5~5.5
水溶解度
12.5 g/L · 12.5g/L(25℃)
Merck
13 · 13,1986
BCS Class
4 · 4
主な用途
法医学と毒物学医薬品(低分子化合物)
InChI
1S/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
InChIKey
AVGYWQBCYZHHPN-CYJZLJNKSA-N
SMILES
N[C@@H](C(N[C@@H]1C(N2[C@]1([H])SCC(C)=C2C(O)=O)=O)=O)C3=CC=CC=C3
CAS データベース
15686 · 15686-71-2(CAS DataBase Reference)
EPAの化学物質情報
5 · 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-, (6R,7R)- (15686-71-2)

化学的性質

化学的特性White cryst. powder

Cephalexin capsules, tablets, and powder for oral suspension should be stored in tight containers at a temperature less than 40 °C, preferably between 15-30 °C. After reconstitution, cephalexin oral suspensions should be stored at 2-8 °C and discarded if not used within 2 wk.

Disposal Methods · 1 件

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

毒性情報

Interactions · 5 件

PROBENECID IS EFFECTIVE IN SLOWING URINARY CLEARANCE & ENHANCING DURATION OF SYSTEMIC ANTIMICROBIAL ACTIVITY /OF CEPHALEXIN/.

...CEPHALOSPORINS...MAY BE AFFECTED BY CONCURRENT USE OF...SULFINPYRAZONE. DIMINISHED TUBULAR SECRETION...RESULT IN HIGHER & MORE SUSTAINED SERUM LEVELS & HENCE, INTENSIFICATION OF DRUG ACTIVITY. /CEPHALOSPORINS/

FUROSEMIDE MAY ENHANCE NEPHROTOXICITY OF CEPHALOSPORINS. /CEPHALOSPORINS/

Hypoprothrombinemia induced by large doses of salicylates and/or cephalosporins, and the gastrointestinal ulcerative or hemorrhagic potential of nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, or sulfinpyrazone may increase the risk of hemorrhage. /Cephalosporins/

For more Interactions (Complete) data for CEPHALEXIN (6 total), please visit the HSDB record page.

Adverse Effects · 1 件

The adverse effects reported by drug manufacturers associated with cephalexin include abdominal pain, diarrhea, dyspepsia, gastritis, nausea, vomiting, erythema multiforme, genital pruritus, vaginitis, vaginal discharge, candidiasis, thrombocytopenia, neutropenia, eosinophilia, arthralgia, arthropathy, and arthritis.

Toxicity Summary · 1 件

Cephalexin is associated with a relatively low incidence of adverse effects in patients when the drug is administered correctly and safely. However, in cases of toxicity or overdose, adverse effects may include soreness of the oral cavity, pruritus of pregnancy, and gastrointestinal symptoms such as nausea, vomiting, epigastric distress, diarrhea, and hematuria. Furthermore, there have been only a few sporadic documented cases of cephalexin leading to fatal episodes of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Human Toxicity Excerpts · 5 件

NEUROTOXICITY, SUCH AS HEADACHE, TINNITUS, ATAXIA, & DIPLOPIA, SOMETIMES DEVELOP; THESE EFFECTS ARE REVERSIBLE. CHANGES IN INTESTINAL & VAGINAL FLORA MAY OCCUR; MONILIASIS IS OCCASIONAL, & OVER GROWTH BY PS AERUGINOSA HAS BEEN REPORTED.

ABOUT 5% OF PATIENTS RECEIVING...SEMISYNTHETIC CEPHALOSPORINS DEVELOP HYPERSENSITIVITY REACTIONS, INCL FEVER, EOSINOPHILIA, SERUM SICKNESS, URTICARIAL OR MORBILLIFORM RASHES, OR ANAPHYLAXIS. TRANSIENT NEUTROPENIA HAS BEEN OBSERVED... /CEPHALOSPORINS/

...CEPHALEXIN, ORALLY ADMIN CEPHALOSPORINS, OCCASIONALLY PRODUCE NAUSEA, VOMITING, & DIARRHEA.

DIRECT POSITIVE COOMBS REACTION IS FREQUENTLY (40%) NOTED WHEN LARGE DOSES OF...CEPHALOSPORINS ARE ADMIN OR WHEN CONVENTIONAL DOSES ARE GIVEN IN PRESENCE OF RENAL DYSFUNCTION. /CEPHALOSPORINS/

For more Human Toxicity Excerpts (Complete) data for CEPHALEXIN (35 total), please visit the HSDB record page.

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Cephalexin

vLess-DILI-concern

4

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Antidote and Emergency TreatmentCEPHALEXIN IS EFFICIENTLY REMOVED FROM CIRCULATION BY HEMODIALYSIS OR PERITONEAL DIALYSIS.
Effects During Pregnancy and Lactation · 2 件

◉ Summary of Use during Lactation

◈ What is cephalexin?

Non-Human Toxicity Values · 4 件

LD50 MOUSE ORAL 1.6-4.5 G/KG /MONOHYDRATE/

LD50 MOUSE INTRAPERITONEAL 0.4-1.3 G/KG /MONOHYDRATE/

LD50 RAT ORAL GREATER THAN 5.0 G/KG /MONOHYDRATE/

LD50 RAT INTRAPERITONEAL GREATER THAN 3.7 G/KG /MONOHYDRATE/

EPA Human Health Benchmarks for Pharmaceuticals · 6 件

Cephalexin

23.3

98.6

The usual adult dose is 250 mg every 6 hours. For some infections, a dosage of 500 mg may be administered every 12 hours.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 1000 mg/day, Lowest Therapeutic Dose (LTD): 12.5 mg/kg-day, and Screening Dose: 0.004 mg/kg-day.

29-Aug-11

法規制情報

FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

安全データ

wgk
3
rtecs
XI0350000
毒性
TDLo orl-hmn: 14 mg/kg/D:GIT AACHAX -,361,68
hs_code
2941905200
risk_code
42/43
hazard_code
Xn
safety_code
22-36/37-45
Hazard Classifications
Resp. Sens. 1Skin Sens. 1
ストレージクラス
11 - Combustible Solids
有毒物質データの
15686-71-2(Hazardous Substances Data)

CEPHALOSPORIN C IS VERY RESISTANT TO ACTION OF PENICILLINASE, FOR WHICH IT IS BOTH COMPETITIVE & NONCOMPETITIVE INHIBITOR, DEPENDING ON SUBSTRATE TESTED... /CEPHALOSPORINS/

Biological Half-Life · 5 件

The half life of cephalexin is 49.5 minutes in a fasted state and 76.5 minutes with food though these times were not significantly different in the study.

LESS THAN 10 TO 15%...IS BOUND TO PLASMA PROTEIN, & PLASMA DRUG CONCN FALL RAPIDLY, T/2 OF CEPHALEXIN NORMALLY BEING ABOUT 40 MIN.

/IN RATS/ RATIOS OF BONE TO SERUM CONCN AVG...1:9 FOR CEPHALEXIN DURING 0.25-4 HR AFTER /ORAL/ DOSING. DESPITE DIFFERENCES IN CONCN; T/2 IN BONE & SERUM WERE SIMILAR.

PEAK TIME, T/2 OF ELIMINATION, T/2 OF ABSORPTION, & VOL OF DISTRIBUTION WERE ALL SIMILAR FOLOWING ADMIN OF EITHER 1 OR 2 G OF CEPHALEXIN.

The serum half-life of cephalexin is 0.5-1.2 hr in adults with normal renal function. The serum half-life of the drug is reported to be about 5 hr in neonates and 2.5 hr in children 3-12 mo of age. In one study, the serum half-life was 7.7 hr in adults with creatinine clearances of 9.2 ml/min and 13.9 hr in adults with creatinine clearances of 4 ml/min.

Metabolism/MetabolitesCephalexin is not metabolized in the body.
FDA Pharmacological Classification · 6 件

5SFF1W6677

CEPHALEXIN ANHYDROUS

Established Pharmacologic Class [EPC] - Cephalosporin Antibacterial

Chemical Structure [CS] - Cephalosporins

Cephalexin anhydrous is a Cephalosporin Antibacterial.

CEPHALEXIN

MeSH Pharmacological ClassificationSubstances that inhibit the growth or reproduction of BACTERIA.
Absorption, Distribution and Excretion · 6 件

Well absorbed from the upper gastrointestinal tract with nearly 100% oral bioavailability. Cephalexin is not absorbed in the stomach but is absorbed in the upper intestine. Patients taking 250mg of cephalexin reach a maximum plasma concentration of 7.7mcg/mL and patients taking 500mg reach 12.3mcg/mL.

Cephalexin is over 90% excreted in the urine after 6 hours by glomerular filtration and tubular secretion with a mean urinary recovery of 99.3%. Cephalexin is unchanged in the urine.

5.2-5.8L.

Clearance from one subject was 376mL/min.

LESS THAN 10 TO 15%...IS BOUND TO PLASMA PROTEIN, & PLASMA DRUG CONCN FALL RAPIDLY... MORE THAN 90%...IS EXCRETED UNALTERED IN URINE WITHIN 6 HR, PRIMARILY BY RENAL TUBULAR SECRETION. ...THERAPEUTICALLY EFFECTIVE CONCN ARE STILL ACHIEVED IN URINE OF PT WITH DECR RENAL FUNCTION.

CEPHALEXIN...IS WELL ABSORBED FROM GI TRACT. PEAK PLASMA CONCN, REACHED @ ABOUT 1 HR AFTER INGESTION OF DRUG, ARE APPROX 9 & 18 UG/ML AFTER ORAL DOSES OF 250 & 500 MG, RESPECTIVELY. INGESTION OF FOOD MAY DELAY ABSORPTION.

Cellular LocationsExtracellular

用途と製造

Uses · 4 件

ANTIBIOTIC FOR INFECTIONS OF THE RESPIRATORY & GENITOURINARY TRACTS & OF THE SKIN, EYE, & BONE; ANTIBIOTIC FOR VETERINARY USE

MEDICATION

MEDICATION (VET):

Use (kg; approx.) in Germany (2009): >1000

U.S. Imports(1979) 2.04X10+7 GRAMS (PRINCPL CUSTMS DISTS)
U.S. Production · 2 件

(1977) PROBABLY GREATER THAN 4.54X10+5 GRAMS

(1979) PROBABLY GREATER THAN 4.54X10+5 GRAMS

Consumption PatternsESSENTIALLY 100% AS AN ANTIBIOTIC
Methods of Manufacturing · 2 件

ACYLATION OF 7-AMINO-3-METHYL-8-OXO-5-THIA-1-AZABICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLIC ACID (PREPARED FROM CEPHALOSPORIN C) WITH 2-PHENYLGLYCINE IN AN APPROPRIATE DEHYDRATING ENVIRONMENT

7-AMINO-3-METHYL-8-OXO-5-THIA-1-AZABICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLIC ACID, WHICH MAY BE PREPD FROM NATURAL ANTIBIOTIC CEPHALOSPORIN C, IS ACYLATED WITH 2-PHENYLGLYCINE IN APPROPRIATE DEHYDRATING ENVIRONMENT.

Formulations/PreparationsCEPHALEXIN, USP (KEFLEX), IS MARKETED AS MONOHYDRATE IN SEVERAL FORMS, INCL CAPSULES OF 250 & 500 MG, ORAL SUSPENSIONS PROVIDING, AFTER RECONSTITUTION, 125 MG/5 ML OR 250 MG/5 ML, & PEDIATRIC DROPS, 100 MG/ML.
Use ClassificationPharmaceuticals -> Animal Drugs -> Approved in Taiwan
General Manufacturing Information · 2 件

RYAN, ET AL, J MED CHEM 12, 310 (1969); MORIN, JACKSON, US PATENT 3,275,626 (1966 TO LILLY)

.../CEPHALEXIN/ SEMISYNTHETIC DERIVATIVE OF CEPHALOSPORIN C.

応用分野 · 6 件

解説セファレキシンは,ペニシリンの母格に類似した β- ラクタム環を基本骨格にもつ第1世代セフェム系抗生物質の一つ。ペニシリンよりも抗菌スペクトルが広く,グラム陽性菌,陰性菌およびレプトスピラに作用する。作用機序はβ-ラクタム環のC-N結合の部分が菌の細胞壁形成酵素と結合し,細胞壁のムコペプチド合成を阻害することによる溶菌作用である。セファログリシン,セファレキシンは経口的に投与し,その他のセファロリジンなどは消化管から吸収されないので,非経口的に投与する。脳脊髄液への移行は少いが,胎盤は通過する。耐薬性は比較的生じにくく,菌交代症も著明なものはみられない。副作用は少いが,大量投与の場合に腎臓障害と,ペニシリン過敏症の患者にアレルギー反応が起ることがあるので,注意を要する。

用途薬理研究用。

用途第 1 世代セフェム系抗生物質 です。ペニシリン結合タンパク質に結合し、 細胞壁の合成阻害作用を示します。抗菌スペ クトルは狭いが、ブドウ球菌などに抗菌作用 を示します。

用途第 1 世代のセファロスポリン 系抗生物質です。ペニシリン結合タンパクに 結合し、細胞壁の合成阻害作用を示します。 抗菌スペクトルは狭いが、ブドウ球菌等に抗 菌作用を示します。

説明Use of the ampicillin-type side chain conveys oral activity to cephalexin. Whereas it no longer has an activating side chain at C-3 and, as a consequence, is somewhat less potent, it does not undergo metabolic deactivation and, thus, maintains potency. It is rapidly and completely absorbed from the GI tract and has become quite popular. Somewhat puzzling is the fact that the use of the ampicillin side chain in the cephalosporins does not result in a comparable shift in antimicrobial spectrum. Cephalexin, like the other first-generation cephalosporins is active against many Gram-positive aerobic cocci but is limited against Gram-negative bacteria. It is a widely used drug, particularly against Gram-negative bacteria causing urinary tract infections, Gram-positive infections (Staphyl ococcus aureus, Streptococcus pneumoni ae and Streptococcus pyogenes) of soft tissues, pharyngitis, and minor wounds.

使用Antibacterial.

上流・下流製品情報

上流原料

ペニシリンGカリウム塩酸アセト酢酸メチル亜鉛 (粉末)
補足説明 · 1 件

定義ChEBI: A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and G am-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.